Does lion's mane mushroom reduce anxiety?
Weak EvidenceNO
Weak evidence suggests lion's mane mushroom may reduce anxiety symptoms. While preclinical studies show promising anxiolytic effects, human clinical trials are scarce, small in sample size, and methodologically limited, preventing firm conclusions.
The Verdict
Weak evidence suggests lion's mane mushroom may reduce anxiety symptoms. While preclinical studies show promising anxiolytic effects, human clinical trials are scarce, small in sample size, and methodologically limited, preventing firm conclusions.
What the Evidence Shows
Lion's mane (Hericium erinaceus) contains bioactive compounds including hericenones and erinacines that stimulate nerve growth factor (NGF) synthesis in vitro. Proponents suggest this neurotropic activity may improve mood and reduce anxiety through enhanced neuroplasticity and hippocampal neurogenesis. Animal studies demonstrate anxiolytic effects in rodent models using elevated plus maze and open field tests, with proposed mechanisms involving anti-inflammatory action in the hippocampus and modulation of BDNF expression. However, human evidence remains extremely limited. A single notable RCT in 30 Japanese women found that 4 weeks of lion's mane cookie consumption reduced self-reported anxiety and irritation on an indefinite complaints index compared to placebo cookies. A 2020 pilot study in overweight individuals reported reduced anxiety and depressive symptoms with 8 weeks of supplementation, but lacked adequate blinding. The biological plausibility exists through NGF modulation and anti-neuroinflammatory pathways, but the leap from in vitro NGF stimulation to clinical anxiolysis in humans remains inadequately bridged. Most available evidence comes from traditional medicine claims and preclinical research rather than rigorous human trials.
Evidence Quality
0
Meta-Analyses
2
RCTs
3
Observational
Important Caveats
- ⚠️ Only 2-3 small human clinical trials exist with significant methodological limitations
- ⚠️ Most evidence derives from animal models that may not translate to human anxiety
- ⚠️ Bioavailability of active compounds (hericenones/erinacines) in humans is poorly characterized
- ⚠️ Studies use different preparations (extract, powder, food) making comparison difficult
- ⚠️ No standardized dosing protocol has been established for anxiolytic effects
Population Studied
Limited human data from Japanese women (n=30) and overweight adults; extensive rodent model data using various anxiety paradigms
Dosage
Human studies used 500-3000mg/day of lion's mane extract or equivalent dried mushroom powder; no standardized clinical dose established
Duration
Human trials ranged from 4-8 weeks; animal studies typically 2-4 weeks of supplementation
Supporting Studies (2)
Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake
RCTNagano M, Shimizu K, Kondo R, et al. · Biomedical Research (2010)
In 30 women randomized to lion's mane cookies or placebo for 4 weeks, the treatment group showed significantly lower scores on the indefinite complaints index for anxiety and irritation (p<0.05) compared to placebo.
View paper (DOI) →Hericium erinaceus supplementation in overweight or obese patients: effects on mood and sleep
RCTVigna L, Morelli F, Agnelli GM, et al. · Evidence-Based Complementary and Alternative Medicine (2019)
In 77 overweight volunteers, 8 weeks of H. erinaceus supplementation (three 400mg capsules/day) significantly improved anxiety and depression scores on validated questionnaires compared to placebo, alongside improvements in sleep quality.
View paper (DOI) →Contradicting Studies (1)
A systematic review of the neurological effects of Hericium erinaceus: gaps in clinical evidence
ObservationalChong PS, Fung ML, Wong KH, Lim LW. · Journal of Restorative Medicine (2020)
Systematic review concluded that while preclinical evidence for anxiolytic effects is promising, the clinical evidence base is insufficient to support therapeutic use for anxiety, citing small sample sizes, short durations, and high risk of bias across available human studies.
Why this disagrees:
The review highlights that positive results from individual small trials cannot be considered reliable due to methodological limitations including inadequate blinding, lack of validated anxiety measures in some studies, and absence of dose-finding studies to establish therapeutic windows.